Meta Information
ID:foxo4-dri
Name:FOXO4-DRI
Schema Version:1.5
Alternate Names
- FOXO4-Peptide Based Inhibitor
- FOXO4-PBI
Active Compound
FOXO4-DRI peptide
Intervention Type
therapeutic_agent
Delivery
Route:
subcutaneous_injection
Scope:
- systemic
Regulatory Status
- us:research_chemical
- eu:research_chemical
Indication
Focus:
healthspan
Description:
Targeting senescent cells to improve tissue function and delay aging.
Typical Protocol
- Experimental protocols in animals involve intermittent subcutaneous injections, often weekly or bi-weekly, over several weeks to induce senescent cell apoptosis.
Expected Cost Mean
Low Cost:
100
High Cost:
500
Cost Type:
monthly
Description:
Experimental peptide cost, not covered by insurance, highly variable.
Summary
FOXO4-DRI is a synthetic peptide designed to disrupt the interaction between the FOXO4 transcription factor and p53 within senescent cells. This disruption leads to the selective apoptosis (programmed cell death) of these harmful cells. By clearing senescent cells, FOXO4-DRI is theorized to reduce chronic inflammation, improve tissue function, and mitigate age-related decline, thereby promoting healthspan.
Purpose
Selectively clears senescent cells to improve tissue function and delay aging.
Card Summary
Experimental peptide targeting senescent cells by disrupting FOXO4-p53 interaction to induce apoptosis, improving tissue function.
Drug Class
null
Drugs In Class
Empty Array
Impact
Score:
3.5
Justification:
Emerging senolytic with promising animal data, limited human evidence.
Evidence
Grade:
C
Score:
3
Justification:
Primarily animal and in-vitro studies, no human clinical trials.
Safety
Score:
6.5
Justification:
Experimental peptide, no human safety data for healthspan, unknown long-term effects.
Flags
- Currently a research chemical, not approved for human therapeutic use.
- No human safety or efficacy data available for healthspan applications.
- Potential for off-target effects and immunogenicity due to peptide nature.
- Long-term risks and optimal dosing in humans are entirely unknown.
Verdict
Promising senolytic in animals, but human data is entirely absent.